NYSE:TEVAPharmaceuticals
Should Teva’s Branded-Drug Pivot and Duvakitug Bet Reshape How TEVA Investors View Earnings Power?
In recent months, Teva Pharmaceutical Industries has accelerated its shift from generics to branded medicines, while absorbing near-term earnings dilution from its Emalex Biosciences acquisition and advancing duvakitug through clinical trials for ulcerative colitis and Crohn’s disease.
This pivot toward higher-margin innovative drugs, with duvakitug viewed as a potential multi-billion-dollar opportunity if trials succeed, is becoming a central focus for how investors assess Teva’s...